LGST SEMPER PARATUS ACQUISITION CORP

Semper Paratus Acquisition Corporation Regains Compliance with Certain Nasdaq Listing Requirement

Semper Paratus Acquisition Corporation Regains Compliance with Certain Nasdaq Listing Requirement

New York, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Semper Paratus Acquisition Corporation (Nasdaq: LGST, the “Company”) announced today that it received a letter from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) confirming that the Company had regained compliance with Nasdaq Listing Rule 5450(b)(2)(A), which requires the Company to maintain a Market Value of Listed Securities (“MVLS”) of $50,000,000 for the continued listing of its securities on The Nasdaq Global Market (the “MVLS Rule”).

As previously disclosed, the Company was notified by the Listing Qualifications Department of Nasdaq that it did not comply with the MVLS Rule. The Company has maintained a MVLS of greater than $50,000,000 for the last ten consecutive business days, from September 14 to September 27, 2023. Accordingly, on September 28, 2023, the Listing Qualifications Department of Nasdaq determined that the Company regained compliance with the MVLS Rule.

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this press release are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential,” “outlook,” “guidance” or the negative of those terms or other comparable terminology. These statements are based on the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause future events to differ materially from those in the forward-looking statements, many of which are outside of the Company’s control. These factors include, but are not limited to, a variety of risk factors affecting the Company’s business and prospects, see the section titled “Risk Factors” in the Company’s Prospectus filed with the SEC on November 5, 2021 and subsequent reports filed with the SEC, as amended from time to time. Any forward-looking statements are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:



EN
29/09/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SEMPER PARATUS ACQUISITION CORP

 PRESS RELEASE

Tevogen Bio Holdings Inc., a Cell Therapy Company, Announces Completio...

Tevogen Bio Holdings Inc., a Cell Therapy Company, Announces Completion of Business Combination and is to be Listed on Nasdaq Under Ticker TVGN Listing on Nasdaq is expected to provide Tevogen Bio Holdings Inc. increased access to capital to accelerate development of its genetically unmodified off-the-shelf T cell therapy products for large patient populations. WARREN, N.J., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen Bio”), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, ...

 PRESS RELEASE

Semper Paratus Acquisition Corporation’s Shareholders Approve Business...

Semper Paratus Acquisition Corporation’s Shareholders Approve Business Combination with Tevogen Bio New York, NY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Semper Paratus Acquisition Corporation (“Semper Paratus”) (Nasdaq: LGST, LGSTW, LGSTU), a publicly-traded special purpose acquisition company, announced today that its shareholders have approved the proposed business combination (the “Business Combination”) with Tevogen Bio Inc, a Delaware corporation (“Tevogen Bio”), at an extraordinary general meeting of Semper Paratus’ shareholders that was held on Wednesday, January 31, 2024 (the “Meeting”...

 PRESS RELEASE

Semper Paratus Acquisition Corporation Announces Anticipated Listing o...

Semper Paratus Acquisition Corporation Announces Anticipated Listing of Tevogen Bio Holdings Inc. on Nasdaq New York, NY, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Semper Paratus Acquisition Corporation (“Semper Paratus”) (Nasdaq: LGST, LGSTW), a publicly-traded special purpose acquisition company, today announced that it has filed a supplement (“Prospectus Supplement”) to its definitive proxy statement/prospectus dated January 10, 2024 (the “Proxy Statement/Prospectus”) for the solicitation of proxies in connection with the extraordinary general meeting of Semper Paratus’ shareholders scheduled ...

 PRESS RELEASE

Tevogen Bio Inc. and Semper Paratus Acquisition Corporation Announce E...

Tevogen Bio Inc. and Semper Paratus Acquisition Corporation Announce Effectiveness of Registration Statement for Business Combination The pro forma equity value of the portion of the combined company attributable to Tevogen Bio Inc (“Tevogen Bio”) stockholders is an expected $1.2 billion.Tevogen Bio is an advanced-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology. New York, NY, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Inc (“Tevogen Bio”), an advanced-stage specialty immunotherapy bi...

 PRESS RELEASE

Semper Paratus Acquisition Corporation Regains Compliance with Certain...

Semper Paratus Acquisition Corporation Regains Compliance with Certain Nasdaq Listing Requirement New York, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Semper Paratus Acquisition Corporation (Nasdaq: LGST, the “Company”) announced today that it received a letter from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) confirming that the Company had regained compliance with Nasdaq Listing Rule 5450(b)(2)(A), which requires the Company to maintain a Market Value of Listed Securities (“MVLS”) of $50,000,000 for the continued listing of its securities on The Nasdaq Global Mark...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch